Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 5/20 | 0.66 |
| ▸ | CES1 | P23141 | 4/20 | 0.66 |
| ▸ | EGFR | P00533 | 1/20 | 0.57 |
| ▸ | MAOA | P21397 | 6/20 | 0.55 |
| ▸ | MAOB | P27338 | 6/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | CAPN9 | O14815 | 1/20 | 0.53 |
| ▸ | CASP3 | P42574 | 1/20 | 0.53 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.51 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.51 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.50 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.50 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.50 |
| ▸ | FLT1 | P17948 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31419932 | 1.00 | TGM2 (0.66) | TGM2CES1EGFRMAOAMAOB | |
| SCHEMBL5323182 | 0.83 | CES1 (0.60) | TGM2CES1EGFRMAOAMAOB | |
| Phenol SCHEMBL672900 | 0.79 | TGM2 (0.75) | TGM2CES1MAOAMAOB | |
| SCHEMBL136581 | 0.79 | TGM2 (1.00) | TGM2CES1MAOAMAOBCA12 | |
| SCHEMBL29505404 | 0.79 | TGM2 (1.00) | TGM2CES1MAOAMAOBCA12 | |
| SCHEMBL9094472 | 0.79 | ACVR1 (0.64) | EGFRMAOAMAOBPDPK1PDGFRB | |
| Water SCHEMBL8100148 | 0.78 | TGM2 (0.96) | TGM2CES1MAOAMAOBCA12 | |
| Methane SCHEMBL28522344 | 0.78 | TGM2 (0.96) | TGM2CES1MAOAMAOBCA12 | |
| SCHEMBL27699846 | 0.77 | EGFR (0.51) | TGM2CES1EGFRMAOAMAOB | |
| SCHEMBL10559920 | 0.77 | EGFR (0.64) | EGFRPDPK1PDGFRBPDGFRAFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113912609-A | Preparation method of natural alkaloid tryptanthrin and derivative thereof | 江苏大学 | 2022-01-11 | — | — | CN | claimed |
| CN-113912609-B | Preparation method of natural alkaloid tryptanthrin and derivatives thereof | 江苏大学 | 2024-01-05 | — | — | CN | disclosed |
| CN-113912609-A | Preparation method of natural alkaloid tryptanthrin and derivative thereof | 江苏大学 | 2022-01-11 | — | — | CN | disclosed |
| US-10889590-B2 | Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents | WILLIAM MARSH RICE UNIVERSITY (US) | 2021-01-12 | — | — | US | disclosed |
| US-10889590-B2 | Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents | WILLIAM MARSH RICE UNIVERSITY (US) | 2021-01-12 | — | — | US | disclosed |
| CN-105899515-B | Derivatives of uncialamycin, method of synthesis and use thereof as antitumor agents | 威廉马歇莱思大学 | 2020-01-14 | — | — | CN | disclosed |
| US-10456400-B2 | Aza-ellipticine analogs, methods of synthesis and methods of treatment | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2019-10-29 | — | — | US | disclosed |
| US-10456400-B2 | Aza-ellipticine analogs, methods of synthesis and methods of treatment | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2019-10-29 | — | — | US | disclosed |
| US-10233192-B2 | Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents | WILLIAM MARSH RICE UNIVERSITY (US) | 2019-03-19 | — | — | US | disclosed |
| US-10233192-B2 | Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents | WILLIAM MARSH RICE UNIVERSITY (US) | 2019-03-19 | — | — | US | disclosed |
| WO-2007132280-A1 | ISATIN AND ITS DERIVATIVES FOR USE AS A MEDICAMENT | Szegedi Tudományegyetem (HU) | 2007-11-22 | — | — | WO | disclosed |
| US-7105529-B2 | Substituted oxindole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors and compositions and methods of treating chemotherapy and radiation therapy side effects | SMITHKLINE BEECHAM CORPORATION (US) | 2006-09-12 | — | — | US | disclosed |
| EP-1009738-B1 | SUBSTITUTED OXINDOLE DERIVATIVES AS PROTEIN TYROSINE KINASE AND AS PROTEIN SERINE/THREONINE KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2004-05-19 | — | — | EP | disclosed |
| US-20030069430-A1 | Substituted oxindole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors and compositions and methods of treating chemotherapy and radiation therapy side effects | SMITHKLINE BEECHAM CORPORATION | 2003-04-10 | — | — | US | disclosed |
| US-6541503-B2 | Preventing chemotherapy induced alopecia. | SMITHKLINE BEECHAM CORPORATION | 2003-04-01 | — | — | US | disclosed |
| US-20030004351-A1 | Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2003-01-02 | — | — | US | disclosed |
| US-6387919-B1 | Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors | GLAXO WELLCOME INC. | 2002-05-14 | — | — | US | disclosed |
| US-6369086-B1 | Substituted oxidole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-04-09 | — | — | US | disclosed |
| EP-1009738-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AS PROTEIN TYROSINE KINASE AND AS PROTEIN SERINE/THREONINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-06-21 | — | — | EP | disclosed |
| WO-1999015500-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AS PROTEIN TYROSINE KINASE AND AS PROTEIN SERINE/THREONINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1999-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10233192-B2 | Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents | UNC119, UNC93B1, RIOX2 | TGM2 949/4885CES1 2056/4885EGFR 1010/4885 |
| US-20030069430-A1 | Substituted oxindole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors and compositions and methods of treating chemotherapy and radiation therapy side effects | SRC, CDK2, CDK1 | TGM2 2342/4885CES1 2172/4885EGFR 156/4885 |
| US-10889590-B2 | Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents | UNC119, UNC93B1, RIOX2 | TGM2 949/4885CES1 2056/4885EGFR 1010/4885 |
| US-10456400-B2 | Aza-ellipticine analogs, methods of synthesis and methods of treatment | AZI2, DNMT1, TET3 | TGM2 2596/4885CES1 1262/4885EGFR 1076/4885 |
| US-20030004351-A1 | Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors | CDK2, CDK1, CCNI | TGM2 2734/4885CES1 1847/4885EGFR 288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.